TABLE OF CONTENTS
1 INTRODUCTION 36
1.1 OBJECTIVES OF THE STUDY 36
1.2 MARKET DEFINITION 36
1.3 OVERVIEW OF THE NORTH AMERICA RADIOTHERAPY MARKET 36
1.4 CURRENCY AND PRICING 38
1.5 LIMITATIONS 38
1.6 MARKETS COVERED 38
2 MARKET SEGMENTATION 41
2.1 MARKETS COVERED 41
2.2 GEOGRAPHICAL SCOPE 42
2.3 YEARS CONSIDERED FOR THE STUDY 43
2.4 DBMR TRIPOD DATA VALIDATION MODEL 44
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
2.6 MULTIVARIATE MODELLING 48
2.7 PRODUCT AND SERVICES SEGMENT LIFELINE CURVE 49
2.8 MARKET END USERS COVERAGE GRID 50
2.9 DBMR MARKET POSITION GRID 51
2.10 VENDOR SHARE ANALYSIS 52
2.11 SECONDARY SOURCES 53
2.12 ASSUMPTIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 56
4.1 PESTLE ANALYSIS 57
4.2 PORTER'S FIVE FORCES MODEL 58
4.3 PRICING ANALYSIS 59
5 REGULATORY GUIDELINES FOR RADIOTHERAPY 61
6 MARKET OVERVIEW 64
6.1 DRIVERS 66
6.1.1 GROWING PREVALENCE OF CANCER DISEASE 66
6.1.2 NOVEL TECHNOLOGY IN RADIOTHERAPY FOR CANCER TREATMENT 66
6.1.3 INCREASING ADOPTION OF RADIOTHERAPY DEVICES AND PROCEDURES 67
6.1.4 RISING PREFERENCE FOR NON-SURGICAL PROCEDURES 67
6.2 RESTRAINTS 67
6.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 67
6.2.2 HIGH COST OF TREATMENT AND RADIOTHERAPY PROCEDURE 68
6.3 OPPORTUNITIES 68
6.3.1 INCREASING HEALTHCARE EXPENDITURE FOR CANCER TREATMENT 68
6.3.2 GROWING GOVERNMENT INITIATIVES TOWARD CANCER TREATMENT 69
6.3.3 RISING PATIENTS AWARENESS TOWARDS CANCER TREATMENT 70
6.4 CHALLENGES 70
6.4.1 STRICT REGULATIONS AND STANDARDS FOR APPROVAL AND COMMERCIALIZATION OF RADIOTHERAPY PRODUCTS 70
6.4.2 RISK OF RADIATION EXPOSURE 71
7 NORTH AMERICA RADIOTHERAPY MARKET, BY PRODUCT & SERVICES 72
7.1 OVERVIEW 73
7.2 SERVICES 75
7.3 PRODUCT 75
7.4 SOFTWARE 75
8 NORTH AMERICA RADIOTHERAPY MARKET, BY TYPE 76
8.1 OVERVIEW 77
8.2 EXTERNAL-BEAM RADIATION THERAPY 79
8.3 INTERNAL RADIATION THERAPY 79
8.4 SYSTEMIC RADIOTHERAPY/ RADIOPHARMACEUTICALS 79
8.5 OTHERS 79
9 NORTH AMERICA RADIOTHERAPY MARKET, BY APPLICATION 80
3.1 OVERVIEW 81
9.1 BREAST CANCER 84
9.2 LUNG CANCER 84
9.3 PROSTATE CANCER 84
9.4 COLORECTAL CANCER 84
9.5 LYMPHOMA 84
9.6 LIVER CANCER 84
9.7 THYROID CANCER 84
9.8 BRAIN CANCER 84
9.9 CERVICAL CANCER 85
9.10 SPINE CANCER 85
9.11 OTHERS 85
10 NORTH AMERICA RADIOTHERAPY MARKET, BY END USER 86
10.1 OVERVIEW 87
10.2 HOSPITALS 89
10.3 RADIATION THERAPY CENTERS 89
10.4 SPECIALTY CLINICS 89
10.5 OTHERS 89
11 NORTH AMERICA RADIOTHERAPY MARKET, BY DISTRIBUTION CHANNEL 90
11.1 OVERVIEW 91
11.2 DIRECT TENDERS 93
11.3 THIRD PARTY DISTRIBUTORS 93
11.4 OTHERS 93
12 NORTH AMERICA RADIOTHERAPY MARKET, BY REGION 94
12.1 NORTH AMERICA 95
13 NORTH AMERICA RADIOTHERAPY MARKET: COMPANY LANDSCAPE 116
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 116
14 SWOT ANALYSIS 117
15 COMPANY PROFILE 118
15.1 SIEMENS HEALTHCARE GMBH 118
15.1.1 COMPANY SNAPSHOT 118
15.1.2 REVENUE ANALYSIS 118
15.1.3 COMPANY SHARE ANALYSIS 119
15.1.4 PRODUCT PORTFOLIO 119
15.1.5 RECENT DEVELOPMENT 119
15.2 ELEKTA 120
15.2.1 COMPANY SNAPSHOT 120
15.2.2 REVENUE ANALYSIS 120
15.2.3 COMPANY SHARE ANALYSIS 121
15.2.4 PRODUCT PORTFOLIO 121
15.2.5 RECENT DEVELOPMENTS 121
15.3 GENERAL ELECTRIC COMPANY 122
15.3.1 COMPANY SNAPSHOT 122
15.3.2 REVENUE ANALYSIS 122
15.3.3 COMPANY SHARE ANALYSIS 123
15.3.4 PRODUCT PORTFOLIO 123
15.3.5 RECENT DEVELOPMENT 123
15.4 HITACHI, LTD. 124
15.4.1 COMPANY SNAPSHOT 124
15.4.2 REVENUE ANALYSIS 124
15.4.3 PRODUCT PORTFOLIO 125
15.4.4 RECENT DEVELOPMENT 125
15.5 KONINKLIJKE PHILIPS N.V. 126
15.5.1 COMPANY SNAPSHOT 126
15.5.2 REVENUE ANALYSIS 126
15.5.3 COMPANY SHARE ANALYSIS 127
15.5.4 PRODUCT PORTFOLIO 127
15.5.5 RECENT DEVELOPMENT 127
15.6 ACCURACY INCORPORATED 128
15.6.1 COMPANY SNAPSHOT 128
15.6.2 REVENUE ANALYSIS 128
15.6.3 PRODUCT PORTFOLIO 129
15.6.4 RECENT DEVELOPMENT 129
15.7 BEBIG MEDICAL. 130
15.7.1 COMPANY SNAPSHOT 130
15.7.2 PRODUCT PORTFOLIO 130
15.7.3 RECENT DEVELOPMENT 130
15.8 BRAINLAB AG 131
15.8.1 COMPANY SNAPSHOT 131
15.8.2 PRODUCT PORTFOLIO 131
15.8.3 RECENT DEVELOPMENTS 131
15.9 CANON MEDICAL SYSTEMS CORPORATION 132
15.9.1 COMPANY SNAPSHOT 132
15.9.2 REVENUE ANALYSIS 132
15.9.3 PRODUCT PORTFOLIO 133
15.9.4 RECENT DEVELOPMENT 133
15.10 ECKERT & ZIEGLER BEBIG 134
15.10.1 COMPANY SNAPSHOT 134
15.10.2 REVENUE ANALYSIS 134
15.10.3 PRODUCT PORTFOLIO 135
15.10.4 RECENT DEVELOPMENT 135
15.11 IBA WORLDWIDE 136
15.11.1 COMPANY SNAPSHOT 136
15.11.2 REVENUE ANALYSIS 136
15.11.3 PRODUCT PORTFOLIO 137
15.11.4 RECENT DEVELOPMENT 137
15.12 LINATECH INC 138
15.12.1 COMPANY SNAPSHOT 138
15.12.2 PRODUCT PORTFOLIO 138
15.12.3 RECENT DEVELOPMENT 138
15.13 MEVION MEDICAL SYSTEMS 139
15.13.1 COMPANY SNAPSHOT 139
15.13.2 PRODUCT PORTFOLIO 139
15.13.3 RECENT DEVELOPMENT 139
15.14 NORDION (CANADA) INC. (A SUBSIDIARY OF SOTERA HEALTH) 140
15.14.1 COMPANY SNAPSHOT 140
15.14.2 PRODUCT PORTFOLIO 140
15.14.3 RECENT DEVELOPMENT 140
15.15 P-CURE 141
15.15.1 COMPANY SNAPSHOT 141
15.15.2 PRODUCT PORTFOLIO 141
15.15.3 RECENT DEVELOPMENT 141
15.16 SHINVA MEDICAL INSTRUMENT CO., LTD. 142
15.16.1 COMPANY SNAPSHOT 142
15.16.2 PRODUCT PORTFOLIO 142
15.16.3 RECENT DEVELOPMENT 142
15.17 UNITED IMAGING HEALTHCARE CO., LTD 143
15.17.1 COMPANY SNAPSHOT 143
15.17.2 PRODUCT PORTFOLIO 143
15.17.3 RECENT DEVELOPMENT 143
15.18 VIEWRAY TECHNOLOGIES, INC. (VIEWRAY) 144
15.18.1 COMPANY SNAPSHOT 144
15.18.2 REVENUE ANALYSIS 144
15.18.3 PRODUCT PORTFOLIO 145
15.18.4 RECENT DEVELOPMENT 145
15.19 ZEISS INTERNATIONAL 146
15.19.1 COMPANY SNAPSHOT 146
15.19.2 REVENUE ANALYSIS 146
15.19.3 COMPANY SHARE ANALYSIS 147
15.19.4 PRODUCT PORTFOLIO 147
15.19.5 RECENT DEVELOPMENT 147
16 QUESTIONNAIRE 148
17 RELATED REPORTS 152

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.